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Abstract
Background: Mitochondria contain their own DNA (MtDNA) that is very sensitive to oxidative stress and as a
consequence could be damaged in quantity. Oxidative stress is largely recognized to play a key role in the
pathogenesis of asthma and COPD and might have a role in the new intermediate phenotype ACOS (asthma-COPD
overlap syndrome). The aim of this study was to investigate MtDNA alterations, as an expression of mitochondrial
dysfunction, in ACOS and to verify whether they might help in the identification of this new phenotype and in its
differentiation from asthma and COPD.
Methods: Ten (10) ACOS according to Spanish guidelines, 13 ACOS according to GINA guidelines, 13 COPD, 14
asthmatic patients and ten normal subjects were enrolled. They further underwent a blood, induced sputum and
exhaled nitric oxide collection. Content of MtDNA and nuclear DNA (nDNA) were measured in the blood cells of
patients by Real Time PCR.
Results: ACOS patients showed an increase of MtDNA/nDNA ratio. Dividing ACOS according to guidelines, those
from the Spanish showed a higher value of MtDNA/nDNA compared to those from GINA/GOLD (92.69 ± 7.31 vs
80.68 ± 4.16). Spanish ACOS presented MtDNA/nDNA ratio closer to COPD than asthma. MtDNA was higher in
asthmatic, COPD, GINA and Spanish ACOS patients compared to healthy subjects (73.30 ± 4.47–137.0 ± 19.45–80.68
± 4.16–92.69 ± 7.31 vs 65.97 ± 20.56).
Conclusion: We found an increase of MtDNA/nDNA ratio in ACOS subjects that led us to conclude that there is
presence of mitochondrial dysfunction in this disease, that makes it closer to COPD than to asthma. Although the
MtDNA/nDNA ratio results are a useful marker for differential diagnosis from asthma, COPD and ACOS, further
studies are needed to confirm the potentiality of MtDNA/nDNA ratio and to a better characterization of ACOS.
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Background
In the spectrum of chronic airways diseases, asthma and
chronic obstructive pulmonary disease (COPD) are the
most frequent. Although they are characterized by clear
differences, some manifestations of both may coexist
and in this situation the clinical condition has been re-
cently called the asthma-COPD overlap syndrome
(ACOS) [1].
Today there are two international guidelines that
might help in classifying ACOS: the Spanish one that
defines ACOS in the presence of two major and two
minor criteria such as very positive bronchodilator test,
eosinophilia in sputum, history of asthma and high total
IgE, personal history of atopy and positive bronchodila-
tor test on two or more occasions [2], and the Global
Initiative for Asthma (GINA) and Global Initiative for
Chronic Obstructive Lung Disease (GOLD) that foresee
that an ACOS patient has a similar number of features of
asthma and COPD. Although a clear interest is today di-
rected to the ACOS, because the recognition of this new
phenotype might change the paradigm of asthma and
COPD management from evidence based to personalized
medicine [3], the main limit to this process remains that
no universal definition criteria still does not exist.
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More than 10.500 studies are present on pubmed on
ACOS, identifying patients affected, sometimes accord-
ing to Spanish and other times to GINA/GOLD guide-
lines. Most of them focused on clinical, functional and
inflammatory differences in ACOS patients compared to
asthmatic and COPD patients [4].
With this study we would like to give our contribution
to the better framing of ACOS among asthma and COPD,
analysing differences in ACOS classified according to
Spanish and GINA/GOLD guidelines. Mitochondria are
independent double membrane organelles found in the
cytosol of eukaryotic cells which are involved in energy
production, cell proliferation, apoptosis and intracellular
calcium homeostasis [5]. The mitochondria genome is a
small (16569-bp), unmethylated DNA molecule that is
present in multiple copies in individual mitochondria [6].
Heteroplasmy is the coexistence of multiple mitochondrial
DNA variants in a single source. Low levels of hetero-
plasmy have been found in almost every healthy individual
who has been studied to date. MtDNA mutations that
have occurred within approximately three human genera-
tions are usually heteroplasmatic. In lung disease, alter-
ations of mitochondria have been evidenced in lung
cancer [7, 8], asthma [9, 10], pneumonia, respiratory fail-
ure, recurrent aspiration, nocturnal hypoventilation,
COPD [11], aging lung [12]. Recently our group reported
an increased mitochondrial DNA in patients affected by
obstructive sleep apnoea (OSA) [13]. We found that
mtDNA/nDNA ratio in OSA patients studied positively
correlated with levels of Reactive Oxygen Metabolites
(ROMs) measured in paired plasma, and therefore we hy-
pothesized that MtDNA/nDNA ratio could be considered
a surrogate oxidative stress marker [13].
Determination of mitochondrial DNA content could
be important for understanding many cellular processes
under different diseases [12].
For example, because mitochondrial DNA is more sus-
ceptible to reactive oxygen species (ROS) induced dam-
age compared to nuclear one, lacking protective histones
and decreasing the DNA repair capacity [14], some au-
thors suggested that it could be used as a marker of oxi-
dative stress [15]. Since the oxidation is common in the
pathogenesis of several lung diseases as obstructive lung
diseases, numerous recent studies analysed mitochon-
drial dysfunction in asthma and COPD. Most authors
agree reporting an increase and a dysfunction of mito-
chondrial DNA in both asthma and COPD [16–18].
However, no studies exist, to our knowledge, on mito-
chondrial DNA analysis in ACOS.
A convenient way to measure mitochondrial DNA
content in a cell is to measure mitochondrial versus nu-
clear genome ratio, termed Mt/N [19]. Mt/N is attractive
as a putative biomarker because it can be measured in a
little as 1 pg of genomic DNA [20].
The aim of this study was to investigate presence of
mitochondrial dysfunction in ACOS measuring Mt/N
DNA for the first time. We aimed to verify the potential-
ity of MtDNA/nDNA in differential diagnosis of ACOS
and give our contribution for a better definition and
characterization of this new phenotype.
Methods
Population
Patients were recruited for the study from the out-
patient facility of the Institute of Respiratory Diseases of
the University of Foggia, Italy. We selected 10 ACOS ac-
cording to Spanish guidelines, 13 ACOS according to
GINA guidelines, 13 COPD patients, 14 asthmatic pa-
tients and ten normal subjects. Written informed con-
sent was obtained from all subjects, and the study was
approved by our institutional ethics committee of Fo-
ggia. Asthmatics were classified and treated according to
GINA guidelines: we chose never–smoker patients with
induced-sputum eosinophilia and with a classic revers-
ibility of 12 % and 200 cc. COPD patients were classified
according to GOLD guidelines: smoker patients with
non reversible airflow limitation at spirometry and with
induced-sputum neutrophilia. Furthermore, we selected
Spanish ACOS patients using two major criteria: very
positive bronchodilator test (increase in FEV1 ≥ 15 %
and ≥400 mL) and eosinophilia in sputum. In
addition we selected GINA ACOS patients; they
should have a similar number of features for both
asthma and COPD (age > 40 and neutrophilia in spu-
tum vs. personal history of asthma and a classic re-
versibility) (Tables 1 and 2).
All subjects enrolled were assessed during a period of
stability and at least 4 weeks after an upper respiratory
tract infection.
At the first visit a complete baseline questionnaire
requesting information on medical history was adminis-
tered to all subjects who were then given a physical
examination, atopy assessment, spirometry with bron-
chial obstruction reversibility test. During the second
visit, subjects underwent a collection of blood, exhaled
nitric oxide (NO) and finally by the sputum induction.
Atopic status
Skin prick test (SPT) was performed for a panel of inhal-
ant allergens as previously described for common aeroal-
lergens (Lofarma, Italy) [21].
Lung function
Pulmonary function tests were performed. Forced ex-
piratory volume in 1 s (FEV1) and forced vital capacity
(FVC) were measured using a spirometer (Sensormedics,
USA). The best value of three maneuvers was expressed
as a percentage of the predicted normal value. After
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baseline evaluation, spirometry was repeated 15 min
after the subjects had inhaled 400 micrograms of salbu-
tamol as previously reported [22].
Reversibility of airways obstruction was expressed in
terms of the percent changes from baseline of the forced
expiratory volume in 1 s (FEV1).
Induced sputum collection and processing
The sputum was induced through inhalation of hyper-
tonic saline solution (4.5 %) with an ultrasonic nebulizer
(DeVilbiss 65; DeVilbiss Corporation,Somerset, PA) in
healthy subjects and in mild asthmatics and analysed
after selection of plug. The collected sputum samples
were examined within 2 h. Selected portions of the spu-
tum sample were chosen through examination with an
inverted microscope, and were weighed. Dithiothreitol
(DTT; Sputolysin; Calbiochem Corp., San Diego, CA),
freshly prepared in a 1:10 dilution with distilled water,
was added in a volume (in microliters) equal to four
times the weight of the selected portion (in milligrams)
of each sputum specimen. The DTT–sputum mixture
was placed in a shaking water bath at 37 ° C for 20 min
and homogenized. It was further diluted with phosphate
buffered saline (PBS) in a volume equal to the sputum
plus DTT. The suspension was filtered through gauze to
remove mucus, and was centrifuged at 2000 rpm for
5 min. The supernatant was aspirated and frozen at−70 °
C for later analysis. The cell pellet was resuspended in a
volume of PBS equal to that of the sputum plus DTT
and PBS preparation described previously. Total cell count
(TCC) and viability (Trypan blue exclusion method) were
determined with a Burkers chamber hemocytometer. The
cell suspension was placed in a Shandon 3 cytocentrifuge
(Shandon Southern Instruments, Sewickley, PA) and
Table 1 Acos according to Spanish and Gina guidelines
ACOS According to Spanish guidelines
Major criteria 1-very positive bronchodilator test (increase in FEV1≥ 15 % and ≥400 mL)
2-Eosinophilia in sputum
3-Personal history of asthma
Minor criteria 1-High levels of total IgE
2-Personal history of atopy
3-Positive bronchodilator test on at least two occasions (increase of FEV1 > 12 % and >200 mL)
ACOS According to GINA guidelines
Criteria A similar number of features of both asthma and COPD, consider the diagnosis of ACOS
Asthma COPD
1-personal history of asthma 1-age > 40
2-Positive bronchodilator test (increase of FEV1 > 12 % and >200 mL) 2-neutrophilia in induced sputum
Table 2 Demographic and Clinical data of patients enrolled
COPD ACOS Spanish Asthma ACOS GINA Healthy subjects p
mean ds mean ds mean ds mean ds mean ds
Age 72 4.78 67.11 6.39 60.67 12.30 61.80 6.25 61.18 3.72 0.0225
BMI 29.45 4.29 28.88 4.46 28.86 5.63 29.70 5.85 27.80 4.64 ns
Atopy (n) 0 4 10 7 0
FEV1 46.88 10.68 72.56 23.40 88.78 17.73 83.60 22.83 90.97 6.33 0.0006
REV 6.37 2.26 18 8.48 18.89 7.63 19.60 4.81 0 0.0004
Smoking habit:
smokers 2 0 0 2
ex smokers 11 8 0 1
never smokers 0 2 14 10 0
P/Y 68.63 32.34 36.83 44.43 0 0 6.60 13 <0.0001
FENO 50 17.63 4.24 23.33 14.84 21.89 11.60 27.30 14.80 10.23 3.50 ns
induced sputum eosinophils 0.58 1.39 4.86 3.18 47.33 26.52 2.10 1.73 0.60 0.80 <0.0001
induced sputum neutrophils 88.66 10.80 82.86 10.64 24.44 20.16 81.20 11.39 27.30 13 <0.0001
BMI: body mass index, FEV1: forced expiratory volume in one 1 s, REV: reversibility of FEV1 after bronchodilatation test with salbutamol, P/Y: pack/year, FENO 50:
Fraction of exhaled nitic oxide at 50 ml/s
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cytospin preparations were made at 450 rpm for 6 min.
Cytospin slides were fixed with methanol and were stained
with May–Grunwald–Giemsa for an overall differential
cell count of 500 nucleated nonsquamous cells. Only sam-
ples with a cell viability > 50 and < 20 % squamous cell
contamination were considered adequate [23].
In severe asthmatic subjects we used the spontaneous
sputum or the sputum produced after inhalation of iso-
tonic saline solution. Three asthmatics, two GINA
ACOS and one Spanish ACOS were not able to produce
adequate sputum samples (defined as containing at least
500 non-squamous cells) and their expectorates were
discharged. The sputum (spontaneous or induced) was
used for cytological analysis.
Measurement of exhaled NO
A rapid-response chemiluminescence NO analyzer
(NIOX MINO, Aerocrine, Cosmed, Roma, Italy) was
used to quantify oxides of nitrogen (NOs). Two-point
calibrations were performed daily using 5.2-parts per
million calibration gas. Exhaled NO (FENO) was mea-
sured using a previously described restricted breath
technique, which employed expiratory resistance and
positive mouth pressure to close the velum and exclude
nasal NO, and a constant expiratory flow of 50 mL/s
and a 350 mL/s. Repeated exhalations were performed
until three plateaus agreed within 5 % [24, 25].
Blood collection and DNA Extraction
A blood sample was obtained in the morning. A total of
3 ml peripheral blood specimens was collected in EDTA
tubes and then were stored at−80°. Whole blood DNA
was extracted with QIAamp DNA MiniKit according to
the manufacturer’s protocol (Qiagen, Hilden, Germany).
The concentration of extracted DNA was measured at
260 nm with NanoDrop Spectrophotometer (Thermo
Scientific NanoDrop, USA) and was adjusted to 10 ng/
μl. Extracted DNA was stored at−20 °C until further use.
Quantitative Real-Time PCR
Mitochondrial DNA content was measured by quantita-
tive real time PCR method using an Applied Biosystems
7300 real-time PCR System (PE Applied Biosystems).
MtDNA was measured by quantification of a unique
mitochondrial fragment relative to a single copy region
of beta-2-microglobulin nuclear gene (β2M). Primers,
Probes (IDT, Integrated DNA Technologies, USA) and
gene accession numbers are listed in Table 3. Mitochon-
drial DNA and β2M probes were labelled at 5’ end with
6 FAM and MAX fluorescent dyes respectively and both
probes contained BHQ-1 as a quencher dye at 3’ end.
The PCR mix was: 1x TaqMan® Universal PCR Master
Mix (PE Applied Biosystems), 200 nM of each primer,
125 nM of TaqMan Probe, 50 ng of total genomic DNA
extract in a 20 μl PCR reaction. Quantitative real-time
PCR conditions were 2 min at 50 °C and 10 min at 95 °
C, followed by 40 cycles of 15 s of denaturation at 95 °C
and 60 s of annealing/extension at 60 °C. The data pre-
sented are the means of 3 measurements. Standard
curves obtained from serial dilutions of PCR-amplified
target sequences were used for the quantification of
MtDNA (Mt) and nuclear genome (N) then the ratio of
Mt/N DNA was calculated.
Analysis
Descriptive statistics (i.e., means, standard deviations,
percentages) were applied to summarize the continuous
and categorical variables. All variables analyzed were
normally distributed and Student’s T-test was used to
compare the mean values. Correlation between MtDNA/
nDNA and clinical, functional and inflammatory data
were assessed using the Spearman’s rank correlation test.
P value < 0,05 was considered significant.
Results
Among the five groups of patients we found a statistically
significant difference only between the age of patients with
asthma and COPD (60.67 ± 12.30 vs 72 ± 4.78, p < 0.05);
while there were no differences regarding the age of the
other groups. Furthermore we found no statistical differ-
ences in BMI among the five groups. Ten (10) asthmatic
subjects, 7 GINA/GOLD ACOS and 4 Spanish ACOS
resulted atopic to prick tests. Thirteen (13) were positive
to dermatophagoides, 3 to dermatophagoides and tree
mix, 2 to alternaria and 3 to mold. FEV1 was lower in
COPD with respect to asthma (46.88 ± 10.68 vs 88.78 ±
17.73, p < 0.05) and with respect to GINA ACOS (46.88 ±
10.68 vs 83.60 ± 22.83) while it was similar to Spanish
Table 3 Primers/probes used in the study
Gene accession number Primer/probe Sequence Product size (bp)
Human mithocondrial genome NC_012920 Mito F TTAAACACATCTCTGCCAAACC 150
Mito R AGATTAGTAGTATGGGAGTGGGA
Mito P AA CCC TAA CAC CAG CCT AAC CAG A
Human β2M accession number M17987 β2M F CTTTCTGGCTGGATTGGTATCT 100
β2M R CAGAATAGGCTGCTGTTCCTAC
β2M P AG TAG GAA GGG CTT GTT CCT GCT G
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ACOS (46.88 ± 10.68 vs 72.56 ± 23.40); also as expected
we found a significant difference between the reversibility
in asthmatic patients and both ACOS groups with respect
to COPD patients. FENO50 was higher in ACOS patients
with respect to Asthma and COPD although there was no
statistically significant difference (Additional file 1).
Considering the induced sputum neutrophilia, asth-
matic patients had a statistically significant low percent-
age (24.44 ± 20.16, p < 0.05) with respect to the other
groups of patients in which we found similar values in-
stead (COPD 88.66 ± 10.80 - Spanish ACOS 82.86 ±
10.64 - GINA ACOS 81.20 ± 11.39; p > 0.05). While con-
sidering induced sputum eosinophilia, although we used
a cut-off >4 % for identifying Spanish ACOS patients, we
found a statistically significant difference only among
asthmatic patients (47.33 ± 26.52, p < 0.05) and the other
3 groups of patients (COPD 0.58 ± 1.39 - Spanish ACOS
4.86 ± 3.18 - GINA ACOS 1.10 ± 1.73).
The MtDNA/nDNA levels in healthy non-smokers was
lower compared to COPD, Spanish ACOS, GINA ACOS
and asthmatic patients (65.97 ± 20.56 vs 137.0 ± 19.45,
92.69 ± 7.31, 80.68 ± 4.16 and 73.30 ± 4.47; p < 0.05).
MtDNA/nDNA resulted higher in COPD compared to
asthmatic patients (137.0 ± 19.45 vs 73.3 ± 4.47, p <
0.005). ACOS patients showed an increase of MtDNA/
nDNA. Dividing ACOS according to guidelines, those
from the Spanish showed significantly higher values of
MtDNA/nDNA compared to those from GINA/GOLD
(92.69 ± 7.31 vs 80.68 ± 4.16, p < 0.05). ACOS patients
according to Spanish guidelines showed higher value of
MtDNA/nDNA compared to asthmatic patients and
lower compared to COPD (92.69 ± 7.31 vs 73.30 ± 4.47,
p < 0.05; 92.69 ± 7.31 vs 137.0 ± 19.45, p = 0.06) (Fig. 1),
while they have lower Ct compared to asthmatic and
higher compared to COPD (Threshold Cycle) (0.70 ±
0.02 vs 0.72 ± 0.02, 0.70 ± 0.02 vs 0.69 ± 0.02; p = 0.03).
ACOS patients according to GINA guidelines presented
similar values of MtDNA/nDNA to asthmatic patients
and significantly different from those of COPD (80.68 ±
4.16 vs 73.30 ± 4.47, p = ns; 80.68 ± 4.16 vs 137.0 ± 19.45,
p < 0.01) (Fig. 1), while they have similar Ct compared to
asthma and higher compared to COPD (0.72 ± 0.01 vs
0.72 ± 0.02, 0.72 ± 0.01 vs 0.69 ± 0.02; p = 0.03) (Fig. 2).
The MtDNA copy number data for several groups of
patients and for healthy subjects were determined using
the quantitative PCR (qPCR) method and were collected
(Fig. 3).
The level of MtDNA/nDNA was correlated with pack/
years (r = 0.54, p < 0.0001) and with percentage of neu-
trophils in the induced sputum (r = 0.45, p < 0.0005)
(Figs. 4 and 5).
Age, body mass index (BMI), atopy, lung function, ex-
haled NO, eosinophils in the induced sputum did not in-
fluence mitochondrial DNA directly.
Discussion
The main result of the study was to report, for the first
time, an increase of the MtDNA/nDNA in ACOS
patients. Analyzing differentially ACOS according to
Spanish guidelines and those to GINA/GOLD we ob-
served that those from GINA/GOLD were similar to the
asthma group although different from COPD while
those from Spanish significantly differed from asthma
and were closer to COPD (Fig. 1).
The entity ACOS has recently been very discussed. Al-
though a great interest is present for this new phenotype
of COPD, mainly for the therapeutic consequences that
it could have, at the moment a big confusion exists
about diagnostic criteria and there is no common defin-
ition. Most international groups prefer to use Spanish
guidelines for the recognition of this entity, others to use
the GINA/GOLD, that however are very difficult to
apply because each clinician can select different paired
characteristics among asthma and COPD. The ongoing
efforts in differential diagnosis of ACOS could not ig-
nore the inflammation [26].
Analyzing singular contributions, ACOS seems to
present either a systemic inflammation characterized by
high sensitivity C reactive protein (PCR) and interleukin
6 in serum and an airways inflammation proved by high
exhaled nitric oxide and neutrophils in the induced spu-
tum [27, 28].
As regards the oxidative stress, no data have ever been
reported although it is largely known that the oxidation
Fig. 1 Differences between ratio Mitochondrial/nuclear DNA in
ACOS according to Spanish or GINA guidelines, asthmatic and COPD
patients. MtDNA/nDNA was higher in all the groups suggesting the
presence of inflammation; ACOS patients present an intermediate
value of MtDNA/nDNA with respect to Asthma and COPD
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is strongly linked to inflammation. In this study, starting
from the hypothesis that both asthma and COPD are
characterized by an increased oxidative stress, we believe
that ACOS, intermediate entity among those, might have
an increase of oxidative stress markers [29]. This study,
born to give our contribution in a clarification of the
disease, offering further data that might help in this con-
fused moment where often ACOS is nicknamed CAOS
supporting the point of view of most clinicians. Actually
different schools of thought identifying ACOS some-
times according to Spanish and other times to GINA/
GOLD guidelines, creating a further confusion and to
add new pathogenetic information to ACOS, might help
the framing of this new phenotype of obstructive lung
diseases.
To better understand ACOS with its characteristics is
very important because we have to remember that pa-
tients affected by the disease, present high personal and
clinical costs having frequent exacerbations, important
respiratory symptoms, reduced physical activity and im-
paired quality of life. Recently, it has been estimated that
they consume from 2 to 6 fold more healthcare re-
sources than those used by asthma and COPD patients
[30–33].
As a marker of mitochondrial dysfunction we chose
the MtDNA/nDNA, recently studied by our group in
Fig. 2 Kinetic curves of MtDNA obtained by q-Real Time PCR in whole blood from ACOS GINA patients. The reported signal (Rn) is calculated by
dividing the amount of florescence emitted by the reporter by the amount of fluorescence emitted by a passive report (log ΔRn). Fluorescence is
plotted vs cycle number
Fig. 3 Comparison of the absolute MtDNA copy number of different groups. The values are represented with arithmetic mean and standard deviation
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the blood of patients with the obstructive sleep apnea. In
our previous study we found a positive correlation be-
tween MtDNA/nDNA and ROMS and suggested that
this marker of mitochondrial dysfunction might also be
used as an indirect marker of oxidative stress. In condition
of oxidative stress, the transcriptional and replication ma-
chinery of mitochondrial biogenesis via replication of the
mitochondrial genome is potentiated and the increase in
mitochondrial DNA quantity resulting detectable in body
fluids [34].
Previous studies analysed mitochondria in other ob-
structive pulmonary diseases reporting an important
pathogenetic role for this microrganelle. For example
Girodet et al. suggested that the mitochondrial genetic
background plays a key role in asthma development [35].
Flaquer et al. highlighted the importance of the mito-
chondria among the factors that contribute to the risk of
asthma [36].
Also regarding COPD, the oxidative DNA damage
seems to be prominent in the mitochondrial genome
and raises the intriguing possibility that genome and
sequence-specific oxidative DNA damage could contrib-
ute to transcriptional dysregulation and cell fate decision
in COPD [37]. Our study is the first analysing MtDNA/
nDNA as a marker of mitochondrial dysfunction in
blood of asthmatic and COPD subjects. Malik et al. pre-
viously suggested that the altered mtDNA levels, de-
scribed in a wide range of human diseases, may directly
contribute to pathology by causing an increased immune
response resulting in chronic inflammation and oxidative
stress and thus contribute to pathogenesis [34].
As expected we found a high quantity of MtDNA/
nDNA that confirms the presence of an increased mito-
chondrial dysfunction in these diseases. The absence of
a correlation between MtDNA/nDNA and positivity to
skin prick tests led us to believe that it is not influenced
by the atopy. For the first time we analysed mitochon-
drial DNA balance also in ACOS reporting an increase
of MtDNA/nDNA in this new phenotype. Our findings
support our hypothesis of increased mitochondrial dys-
function that might be linked to an increased oxidative
stress, probably as a consequence of inflammation, in
ACOS, that was expected considered its common patho-
genetic mechanisms with asthma and COPD. When we
analysed ACOS according to Spanish and GINA/GOLD
guidelines, we observed that the entity selected accord-
ing to major and minor criteria of Spanish guidelines,
presented a close value of MtDNA/nDNA to COPD
while that according to GINA/GOLD to asthma. Al-
though we explored only one pathogenetic aspect of
ACOS, our results leave us to support the idea that
ACOS is a phenotype of COPD and might be classified
according to Spanish guidelines. A further element that
could come in support of our point of view on ACOS
collocation is the positive correlation that we reported
between MtDNA/nDNA and neutrophils. Being either
COPD and ACOS according to Spanish guidelines
joined by the same neutrophilic inflammation, a corre-
lated increase also in MtDNA/nDNA further supports
our hypothesis (Fig. 5).
In this study we further found a positive correlation
between MtDNA/nDNA and pack/years of cigarette
smoked that did not surprise us considering that ciga-
rettes contain a high number of oxidants and further-
more it is a well-recognized cause of oxidative stress
(Fig. 4).
Furthermore, cigarette smoke induces cellular senes-
cence that is involved in the pathogenesis of COPD and
probably to ACOS and leads to impaired mitophagy and
perinuclear accumulation of damaged mitochondria as-
sociated with aging [38]. Previous results of the study of
Aravamudan evidenced the importance of mitochondrial
Fig. 4 Positive correlation between ratio Mitochondrial/nuclear DNA
and pack years. Cigarette smoking is associated with increased
inflammation. This is further demonstrated by the increase
of MtDNA/nDNA
Fig. 5 Positive correlation between ratio Mitochondrial/nuclear DNA
and neutrophils percentage in the induced sputum. The presence of
neutrophils in the sputum is associated with a higher grade
of inflammation
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networks and their regulation in the context of cellular
changes induced by insults such as inflammation in
asthma or cigarette smoke [39].
We agree with Ahmad T et al. that stated that age
could have an influence in determining MtDNA concen-
trations. However, the population of this study and our
previous study on MtDNA were in the middle age popu-
lation and didn’t allow us explore this aspect that re-
quires further study.
The main limitation of this study is the exiguous num-
ber of subjects enrolled for each group. However this is
a pilot study that requires confirmation on a larger
population.
Second, there isn’t a clear consensus about this
method because there is no standard value of MtDNA/
nDNA available upto today, although our group previ-
ously analyzed this marker in other diseases [13].
Third, we didn’t correlate MtDNA/nDNA ratio in our
population with other markers of oxidative stress such
as ROMS that in our previous study help us to suggest
an oxidative role of MtDNA/nDNA. We aim to over-
come this shortcoming with a future study where we will
focus on the oxidative characterization of MtDNA/
nDNA, through the correlation of this marker with
other validated markers of oxidative stress such as
ROMS, 8-isoprostane, reactive oxygen species (ROS);
malondialdehyde (MDA); thiobarbituric acid reacting
substance (TBARS); superoxide; hydroxyl radical (OH);
hydroperoxyl radical (HO2); peroxynitrite (ONOO
−);
hydrogen peroxide (H2O2); nitrogen dioxide (NO2);
myeloperoxidase (MPO); Oxidized low-density lipopro-
tein OxLDL; reduced glutathione (GSH).
Finally, we analyzed the MtDNA/nDNA in blood and
not in airways of subjects enrolled. Because the inflam-
mation and the oxidative stress in asthma and COPD
was reported as either systemic or local, to compare
MtDNA/nDNA in blood and airways might be import-
ant for a more clear understanding of pathogenetic
mechanisms under these diseases and particularly under
ACOS. To overcome this limit we are planning a further
study where we will investigate this aspect.
Conclusion
In conclusion, we reported for the first time an increase
of MtDNA/nDNA in ACOS subjects as mitochondrial
dysfunction. Confirmation of the correlation with other
oxidative stress markers as ROMS could be considered
an indirect expression of an elevated oxidative stress,
and supported clinical potentiality of this new marker.
Since this increase in ACOS patients selected according
to Spanish guidelines is close to COPD, we support the
idea that ACOS could be a phenotype of COPD more
than a new different entity among asthma and COPD. In
consideration of the need-to better characterize ACOS
we evidence the necessity of future clinical and research
contributions in this topic like this study to improve our
understanding of this disease and to achieve the best
management strategies [4].
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